Kou Longfa, Jiang Xinyu, Huang Huirong, Lin Xinlu, Zhang Youting, Yao Qing, Chen Ruijie
Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China.
School of Pharmaceutical Sciences, Wenzhou Medical University, Chashan, Wenzhou 325035, China.
Asian J Pharm Sci. 2020 Mar;15(2):145-157. doi: 10.1016/j.ajps.2020.02.001. Epub 2020 Mar 3.
Tumor cell usually exhibits high levels of reactive oxygen species and adaptive antioxidant system due to the metabolic, genetic, and microenvironment-associated alterations. The altered redox homeostasis can promote tumor progression, development, and treatment resistance. Several membrane transporters are involved in the resetting redox homeostasis and play important roles in tumor progression. Therefore, targeting the involved transporters to disrupt the altered redox balance emerges as a viable strategy for cancer therapy. In addition, nanomedicines have drawn much attention in the past decades. Using nanomedicines to target or reset the redox homeostasis alone or combined with other therapies has brought convincing data in cancer treatment. In this review, we will introduce the altered redox balance in cancer metabolism and involved transporters, and highlight the recent advancements of redox-modulating nanomedicines for cancer treatment.
由于代谢、遗传和微环境相关的改变，肿瘤细胞通常表现出高水平的活性氧和适应性抗氧化系统。氧化还原稳态的改变可促进肿瘤进展、发展和治疗抗性。几种膜转运蛋白参与氧化还原稳态的重置，并在肿瘤进展中发挥重要作用。因此，靶向相关转运蛋白以破坏改变的氧化还原平衡成为一种可行的癌症治疗策略。此外，纳米药物在过去几十年中备受关注。使用纳米药物单独或与其他疗法联合靶向或重置氧化还原稳态在癌症治疗中已带来令人信服的数据。在本综述中，我们将介绍癌症代谢中改变的氧化还原平衡和相关转运蛋白，并重点介绍氧化还原调节纳米药物在癌症治疗中的最新进展。
